Background: In the present study, Tocilizumab(TCZ) was used in patients with COVID-19, who had clinical deterioration and meet the inclusion criteria, previously established by an expert panel (IL-6 >40,, Ferritine >500, PCR >10, Linfopenia <500). Methods: In a single-arm, multicenter (3 private hospital from Lima, Peru), descriptive, retrospective study adult hospitalized COVID-19 patients were included. The clinical and laboratory parameters were collected prior to the administration of TCZ and 24-48 hours after finnishing it. Data was analysed as the mean ± standard deviation for continuous variables and as an absolute value with percentages for categorical variables. The t-student test was used to compare the variables using SPSS, version 23.0. Results: A total of 20 patients (14 men, age 61.9 ± 12.7) with laboratory confirmation (PCR or serological test) for Covid-19 w...

 SARS-CoV-2 (Severe Acute Respiratory Syndrome-related Coronavirus 2) is a new discovered pathogen belonged to the beta-coronavirus family. Its disease was named COVID-19 (Coronavirus Disease 2019). It had been first reported on the city of Wuhan, Province of Hubei, Democratic Republic of China by the end of December of 2019, and it is the responsible of the current pandemic declared by WHO by March 2020.

El SARS-CoV-2 (Síndrome respiratorio agudo severo relacionado a coronavirus 2) es un nuevo patógeno descubierto relacionado con la familia de los beta-coronavirus. Su enfermedad se denominó COVID-19 (Enfermedad por coronavirus 2019). Se informó por primera vez en la ciudad de Wuhan, provincia de Hubei, República Democrática de China a fines de diciembre de 2019, y es el responsable de la pandemia actual declarada por OMS en marzo de 2020.